{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"70"}]}],"title":"Breast : Stage II"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"62"}]}],"title":"Breast : Stage III"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"47"},{"groupId":"OG003","value":"63"}]}],"title":"Breast/Axilla : Stage II"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"54"}]}],"title":"Breast/Axilla : Stage III"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"111"},{"groupId":"OG003","value":"110"}],"units":"Participants"}],"description":"Stage II is (T2,T3, N0, M0) tumor size more than 2 cm but no deep extradermal structure invasion, no regional lymph node metastasis, and no distant metastasis. Stage III is (T4, N0, M0) tumor invasion of deep extradermal structures, no regional lymph node metasis, and no distant metasasis or (Any T, N1, M0) Any tumor size, regional lymph node metastasis, and no distant metastasis.","groups":[{"description":"Patients receive paclitaxel (pac) IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.\n\ndoxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV","id":"OG000","title":"Arm 1 (Pac --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive bevacizumab (bev) IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.\n\ndoxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV bevacizumab: Given IV","id":"OG001","title":"Arm 2 (Pac + Bev --> ddAC + Bev)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.\n\ndoxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV carboplatin: Given IV","id":"OG002","title":"Arm 3 (Pac + Carboplatin --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1, bev as in arm 2, and carboplatin as in arm 3.\n\ndoxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV bevacizumab: Given IV carboplatin: Given IV","id":"OG003","title":"Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at definitive surgery, up to 28 weeks","title":"Pathologic Stage in the Breast and in the Breast Plus Axilla as Measured by American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM) Staging Criteria (Version 6)","type":"SECONDARY","unitOfMeasure":"participants"}